A contrast agent (or contrast medium) is a substance used to increase the contrast of structures or fluids within the body in medical imaging. Gen Consulting Company predicts the contrast agent market in China will grow from USD 2,313 百万 2020 兑美元 5,017 百万 2027, 实现复合年增长率 (复合年增长率) 的 11.7 百分.

该报告提供了有关当前全球市场情况的深入分析和见解, latest trends and drivers into contrast agent market in China. 它提供了对市场规模等各种细节的独家见解, 主要趋势, 竞争格局, 增长率和细分市场. This study also provides an analysis of the impact of the COVID-19 crisis on the contrast agent industry.

The contrast agent market is segmented on the basis of modality, and product. The contrast agent market is segmented as below:

By modality:
– MRI
– X-ray/CT
– 超声波

副产品:
– iodixanol
– iohexol
– iopamidol
– iopromide
– ioversol
– diatrizoate

The report explores the recent developments and profiles of key vendors in the Contrast Agent Market in China, including Bayer AG, Beijing Beilu Pharmaceutical Co., 有限公司, 通用电气公司, Jiangsu Hengrui Medicine Co., 有限公司, Liebel-Flarsheim Company LLC, Shanghai Bolai Kexinyi Pharmaceutical Industry Co., 有限公司, Yangtze River Pharmaceutical Group Co. 有限公司, 除其他外.
*索取免费样品以获得完整的公司列表

历史 & 预测期
本研究报告对各个细分市场进行了分析 2017 到 2027 考虑到 2020 为基准年.

报告范围
– To analyze and forecast the market size of the contrast agent market in China.
– To classify and forecast the contrast agent market in China based on modality, and product.
– To identify and analyze the profile of leading players operating in the contrast agent market in China.

为什么选择这份报告
– Gain a reliable outlook of the contrast agent market in China forecasts from 2021 到 2027 跨场景.
– 确定投资的增长领域.
– 通过公司简介和市场数据领先于竞争对手.
– Excel 格式的跨场景分析易用性的市场预估.
– 三个月的战略咨询和研究支持.
– 为单用户许可证提供打印验证.